Kidney Cancer Drug Sofafenib Receives FDA Priority Review

Drug Industry Daily
KEYWORDS FDA / NDA
A A

The FDA has granted priority review status to sorafenib, the highly anticipated kidney cancer drug developed by Bayer and Onyx Pharmaceuticals.

To View This Article:

Login

Subscribe To Drug Industry Daily